GXI Stock Overview
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Gerresheimer AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €75.60 |
52 Week High | €0 |
52 Week Low | €0 |
Beta | 0.91 |
1 Month Change | 0% |
3 Month Change | 0% |
1 Year Change | 0% |
3 Year Change | 0% |
5 Year Change | 0% |
Change since IPO | 40.26% |
Recent News & Updates
Recent updates
Shareholder Returns
GXI | CH Life Sciences | CH Market | |
---|---|---|---|
7D | 0% | 7.4% | 0.2% |
1Y | 0% | 0.5% | 4.3% |
Return vs Industry: GXI matched the Swiss Life Sciences industry which returned 0.6% over the past year.
Return vs Market: GXI underperformed the Swiss Market which returned 4.4% over the past year.
Price Volatility
GXI volatility | |
---|---|
GXI Average Weekly Movement | 0% |
Life Sciences Industry Average Movement | 5.5% |
Market Average Movement | 3.4% |
10% most volatile stocks in CH Market | 7.7% |
10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: GXI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GXI's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1864 | 11,660 | Dietmar Siemssen | https://www.gerresheimer.com |
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.
Gerresheimer AG Fundamentals Summary
GXI fundamental statistics | |
---|---|
Market cap | CHF3.50b |
Earnings (TTM) | CHF113.17m |
Revenue (TTM) | CHF1.94b |
30.9x
P/E Ratio1.8x
P/S RatioIs GXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GXI income statement (TTM) | |
---|---|
Revenue | €1.99b |
Cost of Revenue | €1.39b |
Gross Profit | €597.31m |
Other Expenses | €481.19m |
Earnings | €116.13m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
Apr 11, 2024
Earnings per share (EPS) | 3.36 |
Gross Margin | 30.01% |
Net Profit Margin | 5.83% |
Debt/Equity Ratio | 66.5% |
How did GXI perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield36%
Payout RatioDoes GXI pay a reliable dividends?
See GXI dividend history and benchmarksGerresheimer dividend dates | |
---|---|
Ex Dividend Date | Jun 06 2024 |
Dividend Pay Date | Jun 10 2024 |
Days until Ex dividend | 72 days |
Days until Dividend pay date | 76 days |
Does GXI pay a reliable dividends?
See GXI dividend history and benchmarks